Author + information
- Received September 10, 2018
- Revision received December 7, 2018
- Accepted December 10, 2018
- Published online April 29, 2019.
- Joel P. Giblett, MDa,b,
- Richard G. Axell, PhDc,
- Paul A. White, PhDc,
- Muhammad Aetesam-Ur-Rahman, MBBSa,b,
- Sophie J. Clarke, PhDb,
- Nicola Figg, BScb,
- Martin R. Bennett, PhDb,
- Nick E.J. West, MDa and
- Stephen P. Hoole, MA, DMa,b,∗ ()
- aDepartment of Interventional Cardiology, Royal Papworth Hospital, Cambridge, United Kingdom
- bDivision of Cardiovascular Medicine, University of Cambridge, Cambridge, United Kingdom
- cMedical Physics and Clinical Engineering, Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom
- ↵∗Address for correspondence:
Dr. Stephen P. Hoole, Department of Interventional Cardiology, Royal Papworth Hospital, Lakeside Cres, Papworth Everard, Cambridge CB23 3RE, United Kingdom.
• GLP-1 protects against ischemic left ventricular dysfunction after serial coronary balloon occlusion of the left anterior descending artery
• This study assessed whether serial right coronary artery balloon occlusion affected the right ventricle in a similar fashion using a conductance catheter method
• Serial balloon occlusion of the right coronary artery causes stunning and cumulative ischemic dysfunction in the right ventricle
• GLP-1 did not protect against stunning and cumulative ischemic dysfunction in the right ventricle
Stunning and cumulative ischemic dysfunction occur in the left ventricle with coronary balloon occlusion. Glucagon-like peptide (GLP)-1 protects the left ventricle against this dysfunction. This study used a conductance catheter method to evaluate whether the right ventricle (RV) developed similar dysfunction during right coronary artery balloon occlusion and whether GLP-1 was protective. In this study, the RV underwent significant stunning and cumulative ischemic dysfunction with right coronary artery balloon occlusion. However, GLP-1 did not protect the RV against this dysfunction when infused after balloon occlusion.
This study was supported by a National Institute for Health Research Healthcare Scientist Doctoral Fellowship Grant (NIHR-HCS-D12-14). Ms. Clarke is an employee of Merck Sharp & Dohme. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.
- Received September 10, 2018.
- Revision received December 7, 2018.
- Accepted December 10, 2018.
- 2019 The Authors